Friedrichs WE - Search Results

1

Nox4 is a Target for Tuberin Deficiency Syndrome.

Shi Q, Viswanadhapalli S, Friedrichs WE, Velagapudi C, Szyndralewiez C, Bansal S, Bhat MA, Choudhury GG, Abboud HE. Shi Q, et al. Among authors: friedrichs we. Sci Rep. 2018 Feb 28;8(1):3781. doi: 10.1038/s41598-018-21838-4. Sci Rep. 2018. PMID: 29491408 Free PMC article.

2

Spleen contributes significantly to increased circulating levels of fibroblast growth factor 23 in response to lipopolysaccharide-induced inflammation.

Bansal S, Friedrichs WE, Velagapudi C, Feliers D, Khazim K, Horn D, Cornell JE, Werner SL, Fanti P. Bansal S, et al. Among authors: friedrichs we. Nephrol Dial Transplant. 2017 Jun 1;32(6):960-968. doi: 10.1093/ndt/gfw376. Nephrol Dial Transplant. 2017. PMID: 27836924 Free PMC article.

3

Spleen contributes significantly to increased circulating levels of fibroblast growth factor23 in response to lipopolysaccharide-induced inflammation.

Bansal S, Friedrichs WE, Velagapudi C, Feliers D, Khazim K, Horn D, Cornell JE, Werner SL, Fanti P. Bansal S, et al. Among authors: friedrichs we. Nephrol Dial Transplant. 2017 Mar 1;32(3):583. doi: 10.1093/ndt/gfx003. Nephrol Dial Transplant. 2017. PMID: 28206605 Free PMC article. No abstract available.

4

NOX4 functions as a mitochondrial energetic sensor coupling cancer metabolic reprogramming to drug resistance.

Shanmugasundaram K, Nayak BK, Friedrichs WE, Kaushik D, Rodriguez R, Block K. Shanmugasundaram K, et al. Among authors: friedrichs we. Nat Commun. 2017 Oct 19;8(1):997. doi: 10.1038/s41467-017-01106-1. Nat Commun. 2017. PMID: 29051480 Free PMC article.

5

Nox4 mediates renal cell carcinoma cell invasion through hypoxia-induced interleukin 6- and 8- production.

Fitzgerald JP, Nayak B, Shanmugasundaram K, Friedrichs W, Sudarshan S, Eid AA, DeNapoli T, Parekh DJ, Gorin Y, Block K. Fitzgerald JP, et al. PLoS One. 2012;7(1):e30712. doi: 10.1371/journal.pone.0030712. Epub 2012 Jan 27. PLoS One. 2012. PMID: 22303451 Free PMC article.

6

HIF-1 Mediates Renal Fibrosis in OVE26 Type 1 Diabetic Mice.

Nayak BK, Shanmugasundaram K, Friedrichs WE, Cavaglierii RC, Patel M, Barnes J, Block K. Nayak BK, et al. Among authors: friedrichs we. Diabetes. 2016 May;65(5):1387-97. doi: 10.2337/db15-0519. Epub 2016 Feb 23. Diabetes. 2016. PMID: 26908870 Free PMC article.

7

Stabilization of HIF-2α through redox regulation of mTORC2 activation and initiation of mRNA translation.

Nayak BK, Feliers D, Sudarshan S, Friedrichs WE, Day RT, New DD, Fitzgerald JP, Eid A, Denapoli T, Parekh DJ, Gorin Y, Block K. Nayak BK, et al. Among authors: friedrichs we. Oncogene. 2013 Jun 27;32(26):3147-55. doi: 10.1038/onc.2012.333. Epub 2012 Aug 6. Oncogene. 2013. PMID: 22869144 Free PMC article.

8

Pharmacodynamic Evaluation of CCI-779, an Inhibitor of mTOR, in Cancer Patients.

Peralba JM, DeGraffenried L, Friedrichs W, Fulcher L, Grünwald V, Weiss G, Hidalgo M. Peralba JM, et al. Clin Cancer Res. 2003 Aug 1;9(8):2887-92. Clin Cancer Res. 2003. PMID: 12912932

9

Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathway.

DeGraffenried LA, Fulcher L, Friedrichs WE, Grünwald V, Ray RB, Hidalgo M. DeGraffenried LA, et al. Among authors: friedrichs we. Ann Oncol. 2004 Oct;15(10):1510-6. doi: 10.1093/annonc/mdh388. Ann Oncol. 2004. PMID: 15367412 Free article.

10

Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.

deGraffenried LA, Friedrichs WE, Russell DH, Donzis EJ, Middleton AK, Silva JM, Roth RA, Hidalgo M. deGraffenried LA, et al. Among authors: friedrichs we. Clin Cancer Res. 2004 Dec 1;10(23):8059-67. doi: 10.1158/1078-0432.CCR-04-0035. Clin Cancer Res. 2004. PMID: 15585641

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

44 results

Search Page